AVLX-144 / Avilex Pharma, Simcere - LARVOL DELTA

Development of Peptide-Based Probes for Molecular Imaging of the Postsynaptic Density in the Brain. (PubMed, J Med Chem) - "Here, we exploit a high-affinity inhibitor of PSD-95, AVLX-144, as a template for developing probes for molecular imaging of the PSD...Notably, we observed diminished tracer binding in human post-mortem Parkinson's disease (PD) brain slices, suggesting postsynaptic impairment in PD. We thus offer a suite of translational probes for visualizing and understanding PSD-related pathologies."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: Avilex Pharma | Recruiting ➔ Completed | Trial completion date: Apr 2021 ➔ Jul 2023 | Trial primary completion date: Feb 2021 ➔ Jul 2023

Trial completion • Trial completion date • Trial primary completion date